NSE INDGN · BSE 544172 · Business Services · NIFTY 500
Indegene Share Price
Indegene Overview
Where the price stands, how it has moved and how it sits against its averages.
Indegene shares last traded at ₹603.80 on the NSE, up 1.10% on the day. That is 2.0% below the 52-week high of ₹616.00 and 45.5% above the 52-week low of ₹414.90. The stock trades at 31.44× earnings, below the sector average of 46.93. Its market value is ₹14,487 Cr.
Price returns
Against the market: 1 Month ▲ +9.49% · 3 Months ▲ +20.17% · 6 Months ▲ +32.05% · This year ▲ +32.21% · 1 Year ▲ +15.28%
Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.
Moving averages — price is above 6 of 6
- Today's price₹603.80
- 5-day average₹595.66 ▲ price 1.4% above
- 20-day average₹589.42 ▲ price 2.4% above
- 10-day average₹586.51 ▲ price 2.9% above
- 50-day average₹558.27 ▲ price 8.2% above
- 100-day average₹537.95 ▲ price 12.2% above
- 300-day average₹514.14 ▲ price 17.4% above
Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.
Indegene Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹3,511 Cr | ▲ +23.6% | ₹401 Cr | 11.4% | ₹16.72 | ₹2.25 |
| FY 2025 | ₹2,839 Cr | ▲ +9.6% | ₹407 Cr | 14.3% | ₹17.15 | ₹2.00 |
| FY 2024 | ₹2,590 Cr | ▲ +12.3% | ₹337 Cr | 13.0% | ₹15.19 | — |
| FY 2023 | ₹2,306 Cr | ▲ +38.5% | ₹266 Cr | 11.5% | ₹11.12 | ₹0.00 |
| FY 2022 | ₹1,665 Cr | ▲ +72.3% | ₹165 Cr | 9.9% | ₹6.89 | ₹0.00 |
| FY 2021 | ₹966 Cr | ▲ +50.3% | ₹149 Cr | 15.5% | ₹7.76 | ₹0.00 |
| FY 2020 | ₹643 Cr | — | −₹6 Cr | −1.0% | ₹2.33 | ₹0.00 |
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹1,063 Cr | ▲ +5.9% | ₹116 Cr | 10.9% | ₹4.81 |
| Q4 FY26 | ₹1,003 Cr | ▲ +6.5% | ₹80 Cr | 7.9% | ₹3.32 |
| Q3 FY26 | ₹942 Cr | ▲ +17.1% | ₹103 Cr | 10.9% | ₹4.26 |
| Q2 FY26 | ₹804 Cr | ▲ +5.7% | ₹102 Cr | 12.7% | ₹4.23 |
| Q1 FY26 | ₹761 Cr | ▲ +0.7% | ₹116 Cr | 15.3% | ₹4.82 |
| Q4 FY25 | ₹756 Cr | ▲ +4.9% | ₹118 Cr | 15.6% | ₹4.92 |
| Q3 FY25 | ₹720 Cr | ▲ +4.9% | ₹110 Cr | 15.2% | ₹4.59 |
| Q2 FY25 | ₹687 Cr | — | ₹92 Cr | 13.4% | ₹3.80 |
Balance sheet — FY26
- Total assets₹4,620 Cr
- Total liabilities₹1,482 Cr
- Shareholders' equity₹3,139 Cr
- Total debt₹144 Cr
- Cash & investments₹1,481 Cr
- Current ratio2.41×
- Revenue growth, 5 yr29.44% a year
- EPS growth, 5 yr16.59% a year
- Operating margin (TTM)12.29%
- Net margin (TTM)10.51%
Cash flow — FY26
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY20–FY26
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total revenue | 642.93 | 966.27 | 1,664.61 | 2,306.13 | 2,589.60 | 2,839.30 | 3,510.50 |
| Cost of revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Operating expenses | 562.28 | 716.44 | 1,458.04 | 1,969.72 | 2,146.50 | 2,369.00 | 3,032.90 |
| Operating income | 80.66 | 249.83 | 206.57 | 336.41 | 443.10 | 470.30 | 477.60 |
| Depreciation | 19.34 | 25.55 | 33.45 | 59.81 | 76.10 | 80.40 | 126.40 |
| Profit before tax | 75.80 | 231.46 | 226.50 | 363.05 | 458.60 | 539.30 | 525.00 |
| Tax | 26.12 | 45.78 | 63.68 | 96.95 | 121.90 | 132.60 | 123.90 |
| Net profit | −6.30 | 149.41 | 164.76 | 266.10 | 336.70 | 406.70 | 401.10 |
| EPS (₹) | 2.33 | 7.76 | 6.89 | 11.12 | 15.19 | 17.15 | 16.72 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | — | 2.00 | 2.25 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total assets | 600.25 | 596.04 | 1,353.47 | 2,203.87 | 2,545.60 | 3,325.90 | 4,620.30 |
| Current assets | 417.57 | 459.29 | 1,130.03 | 1,448.71 | 1,790.80 | 2,530.00 | 2,618.40 |
| Cash & short-term investments | 180.34 | 139.90 | 637.17 | 699.87 | 987.50 | 1,664.30 | 1,481.40 |
| Inventory | 0.00 | 0.00 | 4.68 | 14.05 | 13.30 | 13.10 | 18.90 |
| Property, plant & equipment | 39.62 | 46.42 | 79.88 | 145.62 | 114.40 | 138.50 | 205.80 |
| Total liabilities | 704.93 | 271.53 | 589.57 | 1,140.14 | 1,116.50 | 710.30 | 1,481.60 |
| Current liabilities | 246.59 | 199.43 | 440.44 | 489.15 | 610.90 | 564.50 | 1,086.20 |
| Total debt | 482.86 | 51.39 | 65.75 | 502.58 | 489.60 | 101.60 | 144.40 |
| Total equity | −104.68 | 324.51 | 763.90 | 1,063.72 | 1,429.10 | 2,615.60 | 3,138.70 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| From operations | 22.27 | 117.68 | 297.04 | 130.22 | 507.70 | 441.90 | 650.80 |
| From investing | −18.49 | −24.25 | −160.21 | −893.35 | −327.20 | −682.70 | −512.40 |
| From financing | 136.36 | −131.51 | 233.48 | 333.09 | −66.20 | 287.50 | −82.60 |
| Capital expenditure | −6.05 | −20.62 | −24.71 | −18.83 | −10.70 | −30.00 | −44.30 |
| Dividends paid | — | — | — | — | — | — | −48.00 |
| Net change in cash | 142.85 | −40.50 | 372.92 | −432.69 | 115.00 | 52.40 | 59.80 |
What Analysts Say
Recommendations from 6 analysts who cover Indegene.
▲ 2 bullish (33.3%) · 3 hold (50.0%) · ▼ 1 bearish (16.7%)
Votes
How the votes changed
| Rating | 3M ago | 2M ago | 1M ago | 1W ago | Now | 3-month change |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | — |
| Buy | 1 | 1 | 1 | 1 | 1 | — |
| Hold | 3 | 3 | 3 | 3 | 3 | — |
| Sell | 0 | 0 | 0 | 0 | 0 | — |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | — |
Analyst ratings are opinions, not a guarantee of returns.
Indegene vs Peers
Side by side with other business services companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield | Rating |
|---|---|---|---|---|---|---|---|---|---|
| Indegene | ₹603.80 | ▲ +1.10% | ₹14,487 Cr | 31.44 | 4.55 | 20.72% | 10.51% | 0.38% | This stock |
| Delhivery | ₹421.80 | ▼ −1.06% | ₹31,605 Cr | 226.01 | 3.80 | −4.89% | 1.45% | — | Bearish |
| Urban Company | ₹169.20 | ▼ −1.17% | ₹26,094 Cr | — | 8.89 | — | −15.10% | — | Bullish |
| BLS International Services | ₹222.50 | ▼ −0.49% | ₹9,161 Cr | 14.15 | 3.94 | 31.53% | 24.14% | 0.95% | Bearish |
| Axiscades Technologies | ₹1,947.25 | ▲ +1.16% | ₹8,292 Cr | 83.28 | 9.05 | 8.14% | 6.22% | — | Bullish |
| TVS Supply Chain Solutions | ₹129.90 | ▼ −0.46% | ₹5,732 Cr | 26.67 | 2.95 | 0.47% | 1.06% | — | Bullish |
Rating = the data provider's overall technical view of each peer. Company names link to their own pages.
Indegene Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Valuation Is the price reasonable?
Profitability Of every ₹100 of sales, how much is kept?
Returns & efficiency How well does it use its money?
Growth Is the business getting bigger?
Financial strength Can it pay its bills and debts?
Per share What each share stands for
The share price is 4.63× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 100 metrics from the data provider
Valuation
Per share
Margins
Growth
Financial strength
Returns & efficiency
Price & volume
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
- Dividend yield0.38%
- Payout ratio13.51%
- Latest dividend₹2.25 per share · 31 Jul 2026
Corporate calendar
- MeetingAnnual General Meeting
- Dividend₹2.25 per share · 113% · Final dividend
- BoardQuarterly Results
- BoardAudited Results & Final Dividend
- BoardQuarterly Results & ESOP
- MeetingPostal Ballot
- BoardQuarterly Results
- MeetingPostal Ballot
Show 8 older events
- BoardQuarterly Results
- MeetingAnnual General Meeting
- Dividend₹2.00 per share · 100% · Final dividend
- BoardAudited Results & Final Dividend
- MeetingPostal Ballot
- BoardQuarterly Results & Others
- BoardQuarterly Results
- MeetingAnnual General Meeting
About Indegene
Business Services
Indegene Limited is an India-based tech-native, life sciences commercialization company. The Company provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies. Its segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Brand Activation, and Others. The Enterprise Commercial Solutions business unit caters to the digital marketing operations of life sciences companies. The Enterprise Medical Solutions consolidates large-scale regulatory and medical operations for life sciences companies. The Brand Activation segment offers promotion of biopharmaceutical products and medical devices to HCPs for life sciences companies across channels. It provides customized marketing campaigns through a comprehensive portfolio of proprietary program offerings. Others mainly consist of consultancy and clinical business.
Key people
- Manish GuptaExecutive Chairman of the Board, Chief Executive Officer
- Suhas PrabhuChief Financial Officer
- Sanjay Suresh ParikhExecutive Vice President, Executive Director
- Anand Kiran Praf NijegalExecutive Vice President - Global Operations
- Srishti Ramesh KaushikCompliance Officer, Company Secretary
- Viveksheel GhaiExecutive Vice President - Enterprise Commercial Solutions of Indegene, Inc.
Company facts
- NSE symbolINDGN
- BSE code544172
- ISININE065X01017
- IndustryBusiness Services
- IndexNIFTY 500
- Market cap₹14,487 Cr
- Revenue (FY26)₹3,511 Cr
- Net profit (FY26)₹401 Cr
In the News
Recent headlines about Indegene — they open on Mint in a new tab.
- Top Gainers & Losers on May 4: Meesho, Vedanta, HFCL, BHEL, Cemindia Projects, Anant Raj among top gainers
On May 4, major indices saw gains due to strong buying in heavyweight stocks and positive state election trends for the Bharatiya Janata Party. The Nifty 50 rose 0.51% to 24,119, while the S&P BSE Sensex increased 0.31% to 77,159, with midcap and smallcap indices outperforming.
4 May 2026 · 3 min read · Mint ↗ - Health-tech shines as India’s $283-billion IT sector battles slowing demand
The health-tech sector in India, led by companies such as Sagility and Indegene, has demonstrated resilience, achieving higher revenue increases compared to traditional IT firms. This success is driven by adaptations to US healthcare regulations and a shift towards digital solutions.
8 Dec 2025 · 4 min read · Mint ↗
Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →